PhRMA Foundation: Drug Delivery and Drug Discovery fellowships and grants - varied deadlines, some LOIs required

Sponsor Deadline: 

Sep 1, 2023

Letter of Intent Deadline: 

Apr 14, 2023

Sponsor: 

PhRMA Foundation

UI Contact: 

Sponsor link https://www.phrmafoundation.org/awards/other-opportunities/frontier-award/

The Frontier Award is a new funding opportunity in the PhRMA Foundation’s Value Assessment and Health Outcomes Research (VA-HOR) Program that seeks research proposals for empirical studies testing value assessment frameworks and methods.

Program Description

Although a relatively new area of research, value assessment has become increasingly important as the U.S. moves toward a value-based health care system. Value assessment frameworks are tools for evaluating the relative benefits and costs of health care interventions. While a variety of frameworks exist, some have yet to be applied in a real-world context or evaluated using empirical studies. To advance the field, we need to assess whether these frameworks can reliably guide value assessment, incorporate relevant diverse elements of value, and identify appropriate patient-centered outcomes. Value assessment frameworks can influence the evidence generation process. In particular, the application of these frameworks provides an opportunity for partnerships between stakeholders including patients, researchers, and health care providers.

The Frontier Award is a new funding opportunity in the PhRMA Foundation’s Value Assessment and Health Outcomes Research (VA-HOR) Program that seeks research proposals for empirical studies that apply a published value assessment framework to determine the value of a health care intervention, such as a drug, device, or other health-related technology. Submissions that propose novel approaches to patient-centered value assessment (e.g., expand beyond traditional quality-adjusted survival outcomes) are desired. Projects that involve data collected from patients, utilize real-world data sources, or incorporate health preference evidence are particularly welcomed. Projects that propose methodological advances with no clearly defined patient-partnered data component will not be considered.

Categories: 

Keywords: